Global Oncology Molecular Diagnostic Market – Industry Trends and Forecast to 2030

Oncology Molecular Diagnostic Market Analysis and Size

According to the American Cancer Society's 2020 report, several professional organizations, including the National Comprehensive Cancer Network (NCCN), the American Association of Clinical Oncology (ASCO), and the College of American Pathologists (CAP), have developed biomarker testing and treatment guidelines. Furthermore, the rising cancer prevalence in the country contributes to the region's oncology molecular diagnostics market. According to the National Cancer Institute's (NCI) 2020 Statistics, approximately 1,806,590 cases were diagnosed in the United States in 2020, with the number of cancer survivors expected to reach 2.2 million by 2030. Furthermore, according to the NCI, breast cancer will be the most common cancer type in 2021, accounting for 284,200 cases. These factors are causing an increase in demand for oncology molecular diagnostic market.

Data Bridge Market Research analyses that the oncology molecular diagnostic market which was USD 3.69 billion in 2022, is expected to reach USD 11.45 billion by 2030, at a CAGR of 15.2% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Oncology Molecular Diagnostic Market Scope and Segmentation      

Market Definition

Oncology molecular diagnostics detect cancer cells by examining their biological molecules. Several tests on blood, saliva, and tumour tissue samples are performed to detect and measure specific genetic sequences in DNA, RNA, and cell proteins. Oncology molecular diagnostics aid in the rapid analysis and provision of detailed information, which is then used in the personalized treatment of cancer. These diagnostics solutions are used in clinical and point-of-care (POC) testing for cancer detection. Blood banks are also used to identify pathogens and infectious diseases in donated blood samples.

Oncology Molecular Diagnostic Market Dynamics

Drivers

• Rising prevalence of cancer cases

The rising prevalence of cancer cases around the world is driving up demand for diagnosis, which is driving up the oncology molecular diagnostics market. Cancer was responsible for approximately 10 million deaths in 2020, according to the World Health Organization (WHO). Furthermore, according to the American Cancer Society's 2021 statistics, the global burden of cancer is expected to rise to 27.5 million new cases and 16.3 million cancer deaths by 2040. Such high figures suggest that the estimated rising prevalence of cancer is contributing to the growing need for early detection and preventive medicine. As a result of the abovementioned factors, the demand for oncology molecular diagnostic is steadily increasing.

Opportunities

• New advancements in molecular diagnostics tests

As diagnostic testing technology advances, molecular diagnostics tests for oncology are becoming more popular. Several passages are being made in cancer genome sequencing, computational analysis, tumour models, and innovative cancer research methods. For instance, Roche Molecular Systems, Inc. developed the Cobas EGFR Mutation Test for non-small cell lung cancer patients, which received FDA approval in 2020 and is a real-time PCR test that detects 42 mutations in the epidermal growth factor receptor (EGFR) gene.

Restraints/Challenges

• High cost of molecular diagnostic tests

The high cost of molecular diagnostic tests is a major impediment to the growth of the oncology molecular diagnostic market. The cost of molecular diagnostic testing in cancer care is comparable higher, and it varies depending on the type of therapy. For instance, a molecular diagnostic test for non-small cell lung cancer monotherapy costs around $11,000 to $20,000 per month, and these prices are expected to rise with combination therapy. As a result, the high cost of molecular diagnostic tests is expected to hamper the market for oncology molecular diagnostic.

This oncology molecular diagnostic market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the oncology molecular diagnostic market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Oncology Molecular Diagnostic Market

The COVID-19 pandemic has significantly impacted the oncology molecular diagnostic market. According to 85 percent of respondents in a 2021 study of 164 laboratories conducted by the Association for Molecular Pathology (AMP), molecular testing for cancer decreased between April and June 2020. Furthermore, more than half of respondents stated that oncology testing for clinical trials has reduced due to lower enrolment, aversion to travel, and testing capacity. According to the survey results, the pandemic may have long-term implications for cancer molecular diagnostic testing. Furthermore, cancer research and development institutes and universities worldwide have ceased operations. Furthermore, government funding for research from a variety of institutions is on hold in several parts of the country.

Recent Developments

• In 2021, Amoy Diagnostics Co. Ltd, Riken Genesis Co. Ltd, and Precision Medicine Asia Co. Ltd launched the AmoyDx Pan Lung Cancer PCR Panel. It has been approved for marketing and production in Japan by the Ministry of Health, Labour, and Welfare (MHLW).
• In 2020, Veracyte Inc. and Bayer AG collaborated to advance the Precision Oncology Patient Identification Program in thyroid cancer. The advancement will allow testing with Veracyte's Afirma Xpression Atlas (XA) to identify underlying genomic drivers in tumour cells, and the biomarker-driven therapies may be limited to patients with advanced thyroid cancer.
• In 2020, Danaher (Cepheid) announced a collaboration with Sherlock Biosciences to investigate the development of innovative, ground-breaking molecular diagnostic tests for oncology and infectious diseases using CRISPR technology.

Global Oncology Molecular Diagnostic Market Scope

The oncology molecular diagnostic market is segmented on the basis of type, product, test location, technology, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Cervical Cancer
• Liver Cancer
• Lung Cancer
• Blood Cancer
• Kidney Cancer
• Others

Product

• Instruments
• Reagents
• Others

 Test Location

• Clinics
• Other Establishments
• Point of Care

 Technology

• PCR
• Multiplex
• Others
• In Situ Hybridization
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Chips and Microarrays
• Mass Spectrometry
• Sequencing
• Transcription Mediated Amplification
• Others

 End User

• Hospitals
• Diagnostic Centers

Oncology Molecular Diagnostic Market Regional Analysis/Insights

The oncology molecular diagnostic market is analyzed and market size insights and trends are provided by country, type, product, test location, technology, and end user as referenced above.

The countries covered in the oncology molecular diagnostic market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the oncology molecular diagnostic market because of the prevalence of well-established healthcare infrastructure and the growing number of healthcare infrastructure.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to increasing health conscious people, as a result of increasing cancer occurrences and changes in lifestyle associated with economic development in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The oncology molecular diagnostic market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for oncology molecular diagnostic market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the oncology molecular diagnostic market. The data is available for historic period 2011-2021.

Competitive Landscape and Oncology Molecular Diagnostic Market Share Analysis

The oncology molecular diagnostic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to oncology molecular diagnostic market.

Some of the major players operating in the oncology molecular diagnostic market are:

• Abbott (U.S.)
• Bayer AG (Germany)
• BD (U.S.)
• Agilent Technologies, Inc (U.S.)
• Danaher (U.S.)
• Hologic, Inc. (U.S.)
• QIAGEN (Germany)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Siemens Healthcare Private Limited (Germany)
• Sysmex Singapore Pte. Ltd. (Singapore)
• BIOMÉRIEUX (France)
• DiaSorin Molecular LLC (U.S.)
• Grifols, S.A. (Spain)
• Illumina, Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Leica Biosystems Nussloch GmbH (Germany)
• Analytik Jena GmbH (Germany)
• Biocartis (Belgium)
• GenMark Diagnostics, Inc (U.S.)
• HTG Molecular Diagnostics, Inc. (U.S.)

SKU-57232